Nkarta Inc (NKTX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show bullish momentum, the overbought RSI and significant insider selling suggest caution. Additionally, the company's financial performance is weak, with declining net income and EPS. Without any positive news, analyst upgrades, or strong proprietary trading signals, it is advisable to hold off on investing in this stock for now.

Technical Analysis

The technical indicators show bullish momentum with MACD positively expanding, moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200), and the current price above key resistance levels (R1: 2.591, R2: 2.764). However, the RSI of 84.639 indicates the stock is overbought, suggesting a potential pullback.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Bullish technical indicators such as MACD expansion and moving average alignment. The stock is trading above key resistance levels.

Neutral/Negative Catalysts

Significant insider selling (1947.69% increase in the last month), weak financial performance with declining net income (-23.39% YoY) and EPS (-25.64% YoY), no recent news or positive sentiment, and no recent congress trading data.

Financial Performance

In Q3 2025, Nkarta Inc reported zero revenue growth (0.00% YoY), a net income drop to -$21.72M (-23.39% YoY), and an EPS decline to -0.29 (-25.64% YoY). Gross margin remains at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

5 Analyst Rating

Wall Street analysts forecast NKTX stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 2.700

Low

Averages

12.33

High

Current: 2.700

Low

Averages

12.33

High

Stifel

Buy

downgrade

$12 -> $11

AI Analysis

2025-11-11

Reason

Stifel

Price Target

$12 -> $11

AI Analysis

2025-11-11

downgrade

Buy

Reason

Stifel lowered the firm's price target on Nkarta to $11 from $12 and keeps a Buy rating on the shares. The firm believes management's decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.

Stifel

Stephen Willey

Buy

downgrade

$14 -> $12

2025-08-14

Reason

Stifel

Stephen Willey

Price Target

$14 -> $12

2025-08-14

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Nkarta to $12 from $14 and keeps a Buy rating on the shares. The recent earnings announcement and corporate update did not provide "any incremental surprises" as management is still guiding to the disclosure of preliminary data from the Ntrust-1/2 trials evaluating NKX019 in autoimmune disease before year-end, the analyst tells investors. The firm's reduced price target mostly reflects revised longer-term financing assumptions and valuation, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NKTX

Unlock Now

NKTX Should I Buy

NKTX Should I Buy

Should You Buy Nkarta Inc (NKTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch